Needham Hikes Centessa (CNTA) PT to $38 on High Potential for ORX-750 Trial Success and M&A Appeal

Core Insights - Centessa Pharmaceuticals (NASDAQ:CNTA) is recognized as a promising stock by Wall Street, with analysts projecting strong momentum through 2026 due to upcoming clinical data [1][2][3] Group 1: Analyst Ratings and Price Targets - Needham raised its price target for Centessa to $38 from $35, maintaining a Buy rating, citing the potential for ongoing ORX-750 Phase 2a study data to drive stock momentum [1] - Oppenheimer initiated coverage with an Outperform rating and a price target of $62, increased from $40, highlighting the company's pipeline of orexin agonists as a key factor [2] Group 2: Clinical Developments - Centessa's lead candidate, ORX750, demonstrated potential best-in-class efficacy for treating Narcolepsy Type 1 and Type 2, as well as Idiopathic Hypersomnia, with Phase 2a data showing significant normalization of wakefulness [3] - The company plans a major clinical expansion in Q1 2026, including the launch of the ORX750 registrational program and initiation of studies for ORX142 and ORX489 [3]